🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are escalating around the world, with figures suggesting in excess of 82 million instances annually. Especially elevated rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, the spread of superbugs and the highly restricted available drugs at this time.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

As per data released by a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which combines two antibiotics. The study involved nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to register and commercialise the drug in numerous regions with limited resources.

Doctors treating patients have voiced positive views. Having a single-dose, oral treatment of this kind is described as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.